Upon the treatment of CD73-knockout mice with the combination with anti-CTLA-4 plus anti-PD-1, the tumor burden was significantly alleviated and survival was improved, along with the elevated ratio of the granzyme B+ effector CD8 T cells to the CD206+ macrophages in the TME. The gene discussed is MRC1; the disease is neoplasm.